ACCC logo
Facebook  LinkedIn  Twitter  ACCC Youtube Channel  ACCCBuzz blog

Association of Community Cancer Centers

The leading education and advocacy organization for the multidisciplinary cancer team

ACCCBuzz Blog  Find a Cancer Program  Log in to MyNetwork

Home > Resources > ALK Positive Lung Cancer

ALK Positive Lung Cancer

Testing and Treating ALK+ Non-Small Cell Lung Cancer

Overview

Over the last decade, advances in diagnostics and treatments for lung cancer have led to the development of targeted therapies for some lung cancer subtypes. Patients with ALK+ non-small cell lung cancer (NSCLC) are appropriate candidates for such targeted therapy. This lung cancer subtype is rare (40% of NSCLCs are adenocarcinomas and only 5% of these cancers are ALK+). Biomarker testing is needed to identify patients with this subtype and to determine the most appropriate plan of care. However, this can present unique challenges for community-based providers who may only see a few ALK+ NSCLC patients each year.

About this Project

ACCC launched this project to support community-based practices and programs in the use of precision medicine and molecular testing in caring for patients with ALK+ NSCLC. The primary goal of this initiative is to provide examples of effective practices for utilizing appropriate molecular testing when treating patients with ALK+ NSCLC.

This project explored current barriers and issues related to testing and treating patients with ALK+ NSCLC through an environmental scan, which was also informed by the insights of the project’s expert Advisory Committee.

READ Summary OF FINDINGS

Advisory Committee

ACCC thanks the following individuals for providing their expertise and insight to the Testing and Treating ALK+ NSCLC project:

Copyright © 2017 Association of Community Cancer Centers. All Rights Reserved.
1801 Research Boulevard, Suite 400, Rockville, MD 20850  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US